No Data
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Astellas Pharma Reports Record Revenue and Growth
Astellas Pharma Core Profit Surges 198% in Fiscal 2024
Spot information for individual stocks (1)
Astellas Pharma <4503.T> continues to rise. The core operating profit Financial Estimates for the fiscal year ending March 2026 (consolidated) is expected to be 410 billion yen (a 5% increase from the previous year). Anritsu <6754.T> surges sharply. The consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is expected to be 15 billion yen (a 24% increase from the previous year). AGP <9377.T> hits the upper limit in a buying trend. JAL <9201.T> proposed a stock merger as part of its privatization plan. Fujitsu <6755.T> (under supervision) remains steady. A TOB (public stock purchase) by Paloma Reem Holdings is underway.
April 28th [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Hokkan Holdings <5902> 1,699 yen (4/25) Engaged in food cans, PET bottles, and filling business. The profit forecast for the fiscal year ending March 2025 has been revised upward. The estimated operating profit is 4.5 billion yen (up 2.5% from the previous year). This is an upward revision of about 9% from the previous financial estimates, resulting in a projected increase in profit. Revenue is expected to be lower than the previous forecast, but due to cost reductions in factory expenses and Logistics costs, profit has been upwardly revised. The year-end Dividends have been set at 70 yen.
Astellas Pharma and Hokkan Holdings are in the spotlight, while Nitto Denko and Yamazaki Baking seem to be underperforming.
Last weekend on the 25th, in the US Stocks market, the Dow Jones Industrial Average rose by 20.10 points to 40,113.50, the Nasdaq Composite Index increased by 216.90 points to 17,382.94, and the Chicago Nikkei 225 Futures were up by 220 yen compared to the Osaka daytime at 36,000 yen. The exchange rate was 1 dollar = 143.70-80 yen. In today's Tokyo market, Astellas Pharma <4503>, which experienced a significant increase in operating profit for the fiscal year ending March 2025, at 60.8% growth from a previous financial estimate of a 56.9% decline.
